m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04245)
Name
CAT 1004
Status
Phase 2
TTD Drug ID
D06TZZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
DNA-binding factor KBF1 (p105)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105). [2], [3]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105). [2], [4]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105). [2], [5]
References
Ref 1 Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-KappaB/IL-6 signaling pathway. Cell Mol Life Sci. 2022 May 22;79(6):311. doi: 10.1007/s00018-022-04331-0.
Ref 2 ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Ref 3 m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021 Nov 9;37(6):109968. doi: 10.1016/j.celrep.2021.109968.
Ref 4 WTAP facilitates progression of endometrial cancer via CAV-1/NF-KappaB axis. Cell Biol Int. 2021 Jun;45(6):1269-1277. doi: 10.1002/cbin.11570. Epub 2021 Feb 19.
Ref 5 YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m(6)A modification to activate NF-KappaB and promote the malignant progression of glioma. J Hematol Oncol. 2021 Jul 10;14(1):109. doi: 10.1186/s13045-021-01124-z.